Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

pharmathen s.a., grécko - parikalcitol - 87 - varia i

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

pharmathen s.a., grécko - parikalcitol - 87 - varia i

Európska únia - slovenčina - EMA (European Medicines Agency)

zoetis belgium - inactivated mycoplasma hyopneumoniae, strain p-5722-3, inactivated recombinant chimeric porcine circovirus type 1 containing the porcine circovirus type 2a open reading frame 2 (orf2) protein, inactivated recombinant chimeric porcine circovirus type 1 containing the porcine circovirus type 2b orf2 protein - imunologické prístroje pre sviňovité - ošípané (pre výkrm) - active immunisation of pigs against porcine circovirus type 2 to reduce viral load in blood and lymphoid tissues, fecal shedding and the lesions in lymphoid tissues associated with pcv2 infection. protection was demonstrated against porcine circovirus types 2a, 2b and 2d. active immunisation of pigs against mycoplasma hyopneumoniae to reduce the lung lesions associated with mycoplasma hyopneumoniae infection.  onset of immunity (both vaccination schedules): 3 weeks after (the last) vaccination.  duration of immunity (both vaccination schedules): 23 weeks after (the last) vaccination.  in addition, vaccination has been shown to reduce body weight gain losses under field conditions.

Európska únia - slovenčina - EMA (European Medicines Agency)

amicus therapeutics europe limited - cipaglucosidase alfa - glykogénová choroba typu ii - iné alimentárny trakt a metabolizmus výrobky, - pombiliti (cipaglucosidase alfa) is a long-term enzyme replacement therapy used in combination with the enzyme stabiliser miglustat for the treatment of adults with late-onset pompe disease (acid α-glucosidase [gaa] deficiency).

Európska únia - slovenčina - EMA (European Medicines Agency)

pharmathen s.a. - clopidogrel (as besilate) - peripheral vascular diseases; stroke; myocardial infarction - antitrombotické činidlá - prevencia atherothrombotic eventsclopidogrel je uvedená v:u dospelých pacientov, ktorí trpia infarktu myokardu (od niekoľkých dní až menej ako 35 dní), ischaemic zdvih (od siedmich dní až menej ako šesť mesiacov) alebo zriadené periférneho arteriálneho ochorenia;u dospelých pacientov, ktorí trpia akútneho koronárneho syndrómu:non-st-segmentu-výška akútneho koronárneho syndrómu (nestabilná angína pectoris alebo non-q-vlna, infarkt myokardu), vrátane pacientov podstupujúcich stent umiestnenie týchto perkutánnej koronárnej intervencii, v kombinácii s acetylsalicylová (asa);st-segmentu-výška akútnom infarkte myokardu v kombinácii s asa u medicínsky liečiť pacientov nárok na thrombolytic therapy. prevencia atherothrombotic a thromboembolic udalosti v fibrilácia fibrillationin dospelých pacientov s fibrilácia predsiení, ktorí majú aspoň jeden rizikový faktor cievnych udalosti, nie sú vhodné na liečbu s vitamínom-k antagonisty a ktorí majú nízke riziko krvácania, klopidogrel, je indikovaná v kombinácii s asa pre prevenciu atherothrombotic a thromboembolic udalosti, vrátane mŕtvica.

Európska únia - slovenčina - EMA (European Medicines Agency)

insmed netherlands b.v. - amikacin sulfate - infekcie dýchacích ciest - antibakteriálne pre systémové použitie, - arikayce liposomal is indicated for the treatment of non-tuberculous mycobacterial (ntm) lung infections caused by mycobacterium avium complex (mac) in adults with limited treatment options who do not have cystic fibrosis.

Európska únia - slovenčina - EMA (European Medicines Agency)

laboratorios hipra, s.a. - mycoplasma hyopneumoniae, strain 7304 (nexhyon), expressing the capsid protein of porcine circovirus type 2a, inactivated - immunologicals for suidae, inactivated viral and inactivated bacterial vaccines - ošípané - for the active immunisation of pigs:to reduce lung lesions associated with porcine enzootic pneumonia caused by mycoplasma hyopneumoniae. also, to reduce the incidence of these lesions (as observed in field studies). to reduce viraemia, virus load in lungs and lymphoid tissues and the duration of the viraemic period associated with diseases caused by porcine circovirus type 2 (pcv2). efficacy against pcv2 genotypes a, b and d has been demonstrated in field studies. to reduce culling rate and the loss of daily weight gain caused by mycoplasma hyopneumoniae and/or pcv2 related diseases (as observed at 6 months of age in field studies). mycoplasma hyopneumoniae: onset of immunity: 3 weeks after vaccinationduration of immunity: 23 weeks after vaccinationporcine circovirus type 2:onset of immunity: 2 weeks after vaccinationduration of immunity: 22 weeks after vaccinationin addition, a reduction in nasal and faecal shedding and the duration of nasal excretion of pcv2 was demonstrated in animals challenged at 4 weeks and at 22 weeks after vaccination.

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

leros spol.s r.o., Česká republika - iné liečivá - 94 - fytopharmaca

Európska únia - slovenčina - EMA (European Medicines Agency)

bluebird bio (netherlands) b.v. - autológne cd34+ buniek obohatený obyvateľstva, ktorý obsahuje hematopoietic stem cells transduced s lentiglobin bb305 lentiviral vektor kódovanie beta-a-t87q-globínu gén - beta-thalassemia - other hematological agents - zynteglo je indikovaný na liečbu pacientov 12 rokov a starších s transfúziu-závislé β thalassaemia (tdt), ktorí nemajú β0/β0 genotyp, pre ktorých hematopoetickú kmeňových buniek (hsc) transplantácie je vhodné, ale človek, leukocytové antigénu (hla)-uzavreté súvisiace hsc darcu nie je k dispozícii.

Európska únia - slovenčina - EMA (European Medicines Agency)

agios netherlands b.v. - mitapivat sulfate - genetic diseases, inborn; anemia, hemolytic - other hematological agents - pyrukynd is indicated for the treatment of pyruvate kinase deficiency (pk deficiency) in adult patients (see section 4.